Back to the main directory
Company Analysis / Equity
- Initiating Coverage of Tonix Pharma At Neutral and $1.50 Target by Zacks
- TNXP: A Closer Look at Data from the AtEase Trial of TNX-102 SL in Military-Related PTSD by Zacks
- TNXP: Data from the Phase 2 Clinical Trial of TNX-102 SL in PTSD Coming in the Second Quarter of 2016 by Zacks
- TNXP: PTSD Data to be Reported in the Second Half of May 2016… by Zacks
- TNXP: Positive Topline Data Reported for TNX-102 SL in AtEase Trial by Zacks
- TNXP: TNX-201 Development Stopped; Attention Turns to PTSD and Fibromyalgia… by Zacks
- TNXP: Three Clinical To Be Underway By Mid-Year, Cash Secured, Upgrading to Buy. by Zacks
- TNXP: Tonix Pushing Forward With TNX- 102 SL Despite BESTFIT Miss by Zacks
- TNXP: What Is Tonix Pharmaceuticals Worth? by Zacks
- Tonix Completes Secondary Offering, Uplists to NASDAQ, Initiation of Phase 2/3 Trial Imminent by Zacks
- Tonix Secures $2.4 Million From Private Placement by Zacks
- TSEM: Accelerating Growth and Improved Reporting Should Attract Investors by Zacks
- TSEM: Q3 Earnings In Line, But Invest for Acceleration in Key Product Lines by Zacks
- TSEM: OUTPERFORM; Better Margins Power Higher Earnings by Zacks
- TSEM: Raising Numbers--- End User Markets Are Hot and Should Accelerate Growth by Zacks
- 2Q:16 Report, Partner Outlines Development Plan, Target Price Steady at $12.00. by Zacks
- Earnings Preview. Expect Solid Quarter. Tower moves from 10th to 5th in Foundry Landscape by Zacks
- FDA Approves Probuphine, partner outlines development plan, target price increases to $12.00. by Zacks
- Initiating Coverage by Zacks
- Leadership has its Privileges by Zacks
- Long-Term Story Remains Intact by Zacks
- Long-Term Story Remains Intact; by Zacks
- Nishiwaki Powers Growth in Asia; by Zacks
- Q4 Results, Solid Quarter- Outperform. by Zacks
- Reports 2015 Results; Probuphine Action Date Pushed to May 27; Update on Ropinirole. by Zacks